{
    "clinical_study": {
        "@rank": "99213", 
        "arm_group": [
            {
                "arm_group_label": "Cabozantinib arm 1", 
                "arm_group_type": "Experimental", 
                "description": "Subjects randomized to this arm will receive cabozantinb 40 mg daily with abiratarone and prednisone"
            }, 
            {
                "arm_group_label": "Cabozantinib arm 2", 
                "arm_group_type": "Experimental", 
                "description": "Subjects randomized to this arm will receive cabozantinib 20 mg daily with abiraterone and prednisone"
            }, 
            {
                "arm_group_label": "Cabozantinib arm 3", 
                "arm_group_type": "Experimental", 
                "description": "Subjects randomized to this arm will receive cabozantinb 20 mg every other day with abiraterone and prednisone"
            }, 
            {
                "arm_group_label": "Abiraterone only arm (4)", 
                "arm_group_type": "Active Comparator", 
                "description": "Subjects randomized to this arm will receive abiraterone with prednisone only"
            }
        ], 
        "brief_summary": {
            "textblock": "This study is designed to evaluate the safety and efficacy of combining abiraterone (with\n      prednisone) with cabozantinib in chemotherapy-na\u00efve subjects with bone-metastatic\n      castration-resistant prostate cancer (CRPC)."
        }, 
        "brief_title": "Study of Cabozantinib in Combination With Abiraterone in Chemotherapy-Na\u00efve Subjects With Bone-Metastatic Castration-Resistant Prostate Cancer", 
        "completion_date": {
            "#text": "December 2016", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Prostate Cancer", 
            "Castration Resistant Prostate Cancer", 
            "Prostatic Neoplasms"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Neoplasms", 
                "Prostatic Neoplasms"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Histologically or cytologically confirmed adenocarcinoma of the prostate.\n\n          -  Must be surgically or medically castrated (serum testosterone levels less than or\n             equal to 50 ng/dL)\n\n          -  Must have castration-resistant prostate cancer (CRPC) with disease progression during\n             LHRH therapy or after a surgical bilateral orchiectomy.\n\n          -  Bone metastasis related to prostate cancer\n\n          -  Adequate organ and marrow function\n\n          -  Capable of understanding and complying with the protocol requirements and signed the\n             informed consent document\n\n          -  Sexually active subjects and their partners must agree to use medically accepted\n             methods of barrier contraception (eg, male condom or female condom) as well as one\n             other medically accepted method of contraception during the course of the study\n             treatment and for 4 months after the last dose of study treatment.\n\n        Exclusion Criteria:\n\n          -  Any prior treatment with abiraterone, enzalutamide, or any investigational agents\n             blocking androgen receptor (AR) or androgen synthesis.\n\n          -  Any prior treatment with cabozantinib or participation in a prior clinical trial of\n             cabozantinib.\n\n          -  Any prior cytotoxic therapy (including estramustine) or biologic therapy for the\n             treatment of prostate cancer (a few exceptions will be allowed)\n\n          -  Any prior radionuclide therapy (eg, samarium 153, strontium 89, alpharadin)\n\n          -  Use of investigational agent within 28 days\n\n          -  Any pathological finding consistent with small cell carcinoma of the prostate\n\n          -  Known brain metastases or cranial epidural disease\n\n          -  Diagnosis of another malignancy within 2 years, except for superficial non-melanoma\n             skin cancers, or localized, low grade tumors deemed cured and not treated with\n             systemic therapy"
            }, 
            "gender": "Male", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "280", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 14, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01995058", 
            "org_study_id": "XL184-210"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Cabozantinib arm 1", 
                    "Cabozantinib arm 2", 
                    "Cabozantinib arm 3"
                ], 
                "description": "Tablets taken orally", 
                "intervention_name": "cabozantinib", 
                "intervention_type": "Drug", 
                "other_name": "XL184"
            }, 
            {
                "arm_group_label": [
                    "Cabozantinib arm 1", 
                    "Cabozantinib arm 2", 
                    "Cabozantinib arm 3", 
                    "Abiraterone only arm (4)"
                ], 
                "description": "Tablets taken orally daily", 
                "intervention_name": "abiraterone", 
                "intervention_type": "Drug", 
                "other_name": [
                    "Zytiga(R)", 
                    "abiraterone acetate"
                ]
            }, 
            {
                "arm_group_label": [
                    "Cabozantinib arm 1", 
                    "Cabozantinib arm 2", 
                    "Cabozantinib arm 3", 
                    "Abiraterone only arm (4)"
                ], 
                "description": "Tablets taken orally twice daily", 
                "intervention_name": "prednisone", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Prednisone"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "CRPC", 
            "castration resistant prostate cancer", 
            "prostate cancer"
        ], 
        "lastchanged_date": "April 4, 2014", 
        "location": [
            {
                "contact": {
                    "email": "dgarrett@azpoh.com", 
                    "last_name": "Deana Garrett", 
                    "phone": "480-860-5000"
                }, 
                "facility": {
                    "address": {
                        "city": "Scottsdale", 
                        "country": "United States", 
                        "state": "Arizona", 
                        "zip": "85258"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "Tracy.Drennan@mckesson.com", 
                    "last_name": "Tracey Drennen", 
                    "phone": "281-863-4689"
                }, 
                "facility": {
                    "address": {
                        "city": "Sedona", 
                        "country": "United States", 
                        "state": "Arizona", 
                        "zip": "86336"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "Julie.Klinker@usoncology.com", 
                    "last_name": "Julie Klinker", 
                    "phone": "520-269-3821"
                }, 
                "facility": {
                    "address": {
                        "city": "Tucson", 
                        "country": "United States", 
                        "state": "Arizona", 
                        "zip": "85710"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "Tracy.Drennan@mckesson.com", 
                    "last_name": "Tracey Drennen", 
                    "phone": "281-863-4689"
                }, 
                "facility": {
                    "address": {
                        "city": "Oxnard", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "93030"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "karen.morris@usoncology.com", 
                    "last_name": "Karen Morris", 
                    "phone": "303-418-7669"
                }, 
                "facility": {
                    "address": {
                        "city": "Aurora", 
                        "country": "United States", 
                        "state": "Colorado", 
                        "zip": "80012"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "mike.wacker@ucdenver.edu", 
                    "last_name": "Mike Wacker", 
                    "phone": "720-848-4020"
                }, 
                "facility": {
                    "address": {
                        "city": "Aurora", 
                        "country": "United States", 
                        "state": "Colorado", 
                        "zip": "80045"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "mmelink@negacancer.com", 
                    "last_name": "Megan Melink", 
                    "phone": "706-353-2990", 
                    "phone_ext": "284"
                }, 
                "facility": {
                    "address": {
                        "city": "Athens", 
                        "country": "United States", 
                        "state": "Georgia", 
                        "zip": "30607"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "ajohnston@piedmontcancerinstitute.com", 
                    "last_name": "Ann Johnston", 
                    "phone": "678-298-3235"
                }, 
                "facility": {
                    "address": {
                        "city": "Atlanta", 
                        "country": "United States", 
                        "state": "Georgia", 
                        "zip": "30318"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "nwilliams@illinoiscancercare.com", 
                    "last_name": "Nancy Williams", 
                    "phone": "309-243-3614"
                }, 
                "facility": {
                    "address": {
                        "city": "Peoria", 
                        "country": "United States", 
                        "state": "Illinois", 
                        "zip": "61615"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "pat.stone@cancercenterofkansas.com", 
                    "last_name": "Pat Stone", 
                    "phone": "316-613-4313"
                }, 
                "facility": {
                    "address": {
                        "city": "Wichita", 
                        "country": "United States", 
                        "state": "Kansas", 
                        "zip": "67214"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "Tracy.Drennan@mckesson.com", 
                    "last_name": "Tracey Drennen", 
                    "phone": "281-863-4689"
                }, 
                "facility": {
                    "address": {
                        "city": "Las Vegas", 
                        "country": "United States", 
                        "state": "Nevada", 
                        "zip": "89148"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "amy.dewitt2@usoncology.com", 
                    "last_name": "Amy DeWitt", 
                    "phone": "919-571-7436"
                }, 
                "facility": {
                    "address": {
                        "city": "Raleigh", 
                        "country": "United States", 
                        "state": "North Carolina", 
                        "zip": "27607"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "Tamyra.Batsch@usoncology.com", 
                    "last_name": "Tamyra Batsch", 
                    "phone": "360-597-1358"
                }, 
                "facility": {
                    "address": {
                        "city": "Tualatin", 
                        "country": "United States", 
                        "state": "Oregon", 
                        "zip": "97062"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "d.mcneal@choasc.com", 
                    "last_name": "Deborah McNeal", 
                    "phone": "843-266-2540"
                }, 
                "facility": {
                    "address": {
                        "city": "Charleston", 
                        "country": "United States", 
                        "state": "South Carolina", 
                        "zip": "29414"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "gnorris@ghs.org", 
                    "last_name": "Gina Norris", 
                    "phone": "864-242-2762"
                }, 
                "facility": {
                    "address": {
                        "city": "Greenville", 
                        "country": "United States", 
                        "state": "South Carolina", 
                        "zip": "29605"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "sharrelson@atlanticurologyclinics.com", 
                    "last_name": "Stacey Harrelson", 
                    "phone": "843-286-0119"
                }, 
                "facility": {
                    "address": {
                        "city": "Myrtle Beach", 
                        "country": "United States", 
                        "state": "South Carolina", 
                        "zip": "29572"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "Tracy.Drennan@mckesson.com", 
                    "last_name": "Tracey Drennen", 
                    "phone": "281-863-4689"
                }, 
                "facility": {
                    "address": {
                        "city": "Dallas", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "75246"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "jamie.renard@usoncology.com", 
                    "last_name": "Jamie Renard", 
                    "phone": "713-467-1722"
                }, 
                "facility": {
                    "address": {
                        "city": "Houston", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "77024"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "dholani.zarook@hci.utah.edu", 
                    "last_name": "Dholani Zarook", 
                    "phone": "801-587-4776"
                }, 
                "facility": {
                    "address": {
                        "city": "Salt Lake City", 
                        "country": "United States", 
                        "state": "Utah", 
                        "zip": "84112"
                    }
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "4", 
        "official_title": "A Randomized Phase 2 Study of Cabozantinib (XL184) in Combination With Abiraterone in Chemotherapy Na\u00efve Subjects With Bone-Metastatic Castration-Resistant Prostate Cancer", 
        "other_outcome": [
            {
                "description": "Subjects are followed for safety as assessed by adverse events at least through 30 days after the date of a decision to permanently discontinue study treatment.", 
                "measure": "Safety and tolerability as assessed by adverse events", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 18 months"
            }, 
            {
                "description": "When administered in combination, both cabozantinib and abiraterone plasma concentrations will be measured prior to dosing on selected visits", 
                "measure": "Pharmacokinetic Pre-dose Plasma Concentrations of both cabozantinib and abiraterone when administered in combination", 
                "safety_issue": "No", 
                "time_frame": "Days 1-4, Week 3, Week 5, Week 7, Week 9, Week 17, and Week 41"
            }, 
            {
                "description": "Overall survival is defined as the time from randomization to death from any cause.", 
                "measure": "Overall survival", 
                "safety_issue": "No", 
                "time_frame": "Up to 36 months"
            }, 
            {
                "description": "Bone scans will be evaluated by an independent radiology facility for response", 
                "measure": "Bone scan response by computer-aided detection (CAD)", 
                "safety_issue": "No", 
                "time_frame": "Up to 18 months"
            }, 
            {
                "description": "For selected subjects, the plasma AUC of cabozantinib and abiraterone will be measured at Week 5", 
                "measure": "Pharmacokinetic Plasma Area Under the Curve (AUC)", 
                "safety_issue": "No", 
                "time_frame": "Week 5"
            }
        ], 
        "overall_contact": {
            "last_name": "Exelixis Clinical Trials", 
            "phone": "1-888-393-5494"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "June 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "PFS is defined as the time from randomization to the earlier of the following events: disease progression or death due to any cause", 
            "measure": "Radiographic progression free survival (PFS)", 
            "safety_issue": "No", 
            "time_frame": "Up to 18 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01995058"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Exelixis", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Exelixis", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "December 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}